FDA Reviews RSV Drugs; Kennedy Re-evaluates Vaccine Recommendations

The Food and Drug Administration is reviewing the safety of two injectable drugs, from Merck and Sanofi, used to protect babies and toddlers from RSV, a common respiratory virus. These drugs, not vaccines, are laboratory-made antibodies that help the immune system fight off the virus. The review comes as health officials, under Secretary Kennedy, re-evaluate routine childhood vaccinations. Merck and Sanofi have not identified any new safety concerns with their medications. The CDC recommends these antibody shots for infants born just before or during RSV season, and for some eight-to-nineteen-month-olds at higher risk. Secretary Kennedy has replaced every member of the CDC committee that makes vaccine recommendations, and the FDA is scrutinizing the safety of other vaccines, including COVID-19 shots. The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.